UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008253
Receipt number R000009695
Scientific Title A Randomized Clinical Trial of Transcatheter Arterial Infusion (TAI) appending to Radio Frequency Ablation Therapy for Hepatocellular Carcinoma
Date of disclosure of the study information 2012/06/25
Last modified on 2013/01/24 14:18:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized Clinical Trial of Transcatheter Arterial Infusion (TAI) appending to Radio Frequency Ablation Therapy for Hepatocellular Carcinoma

Acronym

Transcatheter Arterial Infusion (TAI) appending to Radio Frequency Ablation Therapy for Hepatocellular Carcinoma

Scientific Title

A Randomized Clinical Trial of Transcatheter Arterial Infusion (TAI) appending to Radio Frequency Ablation Therapy for Hepatocellular Carcinoma

Scientific Title:Acronym

Transcatheter Arterial Infusion (TAI) appending to Radio Frequency Ablation Therapy for Hepatocellular Carcinoma

Region

Japan


Condition

Condition

Hepatocellular Carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To confirm whether transacatheter arterial infusion of CDDP suppress the recurrence rate of HCC curatively treated by radiofrequency ablation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

recurrence-free survival, recurrence rate(local, distant)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

RFA only.

Interventions/Control_2

Transcatheter arterial infusion of CDDP(65mg/m2) before RFA.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Histologically or clinically diagnosed hepatocellular carcinoma.
2)Patients who do not want surgery or other percutaneous local therapy. History of local ablation is limited up to two times.
3)With measurable tumor in the liver, and without extrahepatic metastasis.
4)Performance Status:0-1
5)Child-Pugh:A or B
6)A case the function of the main organ (marrow, kidney, heart) is maintained enough and to meet a standard of the following clinical inspection.
1)WBC:more than 3000/mm3
2)Platelet:more than 5x104/mm3
3)Hb:more than 9.5g/dL
4)serum creatinine:less than 1.2mg/dL
5)BUN:less than 25mg/dL
6)Prothrombin time:more than 50%
7)Total bilirubin:<3.0mg/dL

Key exclusion criteria

1)Severe complications excluding cirrhosis.
2)Active other cancers.
3)History of severe allergy.
4)Pregnant or maybe pregnant, breast-feeding.
5)A case have plan to use interferon during this study period.

Target sample size

90


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sinpei Sato

Organization

Kyoundo Hospital

Division name

gastroenterology and hepatology

Zip code


Address

1-8 Kandasurugadai, Chiyoda-Ku, Tokyo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kyoundo Hospital

Division name

gastroenterology and hepatology

Zip code


Address

1-8 Kandasurugadai, Chiyoda-Ku, Tokyo

TEL


Homepage URL


Email



Sponsor or person

Institute

Kyoundo Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 06 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 05 Month 29 Day

Date of IRB


Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 06 Month 25 Day

Last modified on

2013 Year 01 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009695


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name